# Orchestra BioMed Holdings, Inc. (OBIO)

> Source: Nexqual · https://nexqual.com/OBIO · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Orchestra BioMed Holdings, Inc. (OBIO), nexqual.com/OBIO" · informational, not investment advice.

**Price:** USD 6.09 (+1.67% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 5.99 · day 6–6.16 · 52w 3.46–6.5 · market cap $366M · NGM

## Key facts
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 12.43 (range 9–20).
- Total return with dividends: 1Y +49.4% vs S&P 500 +14.8%; 5Y -38.2% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05 (date not yet confirmed by the company), EPS estimate USD -0.4, revenue estimate $104K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: OBIO paid no cash dividend in the last five years.
- Short interest: 6.90% of float (as of 2026-10-15), 8.1 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 11.3x · EV/Sales 8.5x · P/B 18.6x · FCF yield -16.42% · Earnings yield -16.40% · Net cash $89.5M · EV $271M

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 12.43 (low 9, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | Chardan Capital | Maintained | Buy | $20 |
| 2026-09-15 | B. Riley Securities | Target raised | Buy | $10 → $11 |
| 2026-09-10 | BTIG | Upgrade | Neutral → Buy | $10 |
| 2026-08-11 | Piper Sandler | Target raised | Overweight | $9 → $10 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +49.4% | -38.2% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +49.8% | -9.2% |
| Volatility (annualized) | 62.7% | 76.5% |
| Max drawdown | -34.8% (Nov 2025→Jan 2026) | -88.7% (Apr 2023→Sep 2025) |

## Dividends
OBIO paid no cash dividend in the last five years.

## Short interest
2,552,988 shares sold short, 6.90% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,372,557 shares (+7.6%). Days to cover: 8.1 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/OBIO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.40 | $-0.38 | −$0.02 | $103,500 | 6 |
| Next quarter (ends 2026-12-31) | $-0.41 | $-0.41 | −$0.01 | $106,830 | 6 |
| Current fiscal year (ends 2026-12-31) | $-1.52 | $-1.50 | −$0.02 | $451,140 | 6 |
| Next fiscal year (ends 2027-12-31) | $-1.51 | $-1.46 | −$0.05 | $600,140 | 6 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2027-05-21 (includes earnings 2026-11-05): ±53.7%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2027-05-21 | 204 | 100.7% | ±53.7% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.37 | −$0.37 | In line | — |
| — | Quarter ended Dec 31, 2025 | $0.26 | −$0.38 | Beat +$0.64 | — |
| — | Quarter ended Sep 30, 2025 | −$0.40 | −$0.43 | Beat +7.0% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).